Halifax, Nova Scotia – (Newsfile Corp. – November 18, 2021) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (ESF: AHUH) (“Sixth Wave”, “SIXW” or the “Company”) is pleased to provide an update on the commercialization of the Affinity ™ System (the “System”) for cannabinoid purification. Green Envy Extracts (customer) will build its production line in Michigan on or around December 15, 2021. Production has begun, SIXW will use the crude extract to complete functionality tests on affinity’s formula. Tests will be performed 3 weeks earlier than planned. SIXW has also completed the manufacture of Affinity nanotechnology beads ™ for use in Affinity ™. large-scale production formula scheduled to be installed in Michigan. By the end of the year, SIXW will manufacture 3 additional ball orders that are expected to complement 4 Affinity ™ production formulas.
“We are very excited to continue our collaboration with Sixth Wave on the launch of the Affinity ™ formula,” said Amato Spagnoletti, [Director] of Green Envy. “As a multi-state developing hashish operator, our respective generation approaches will bring significant technical and commercial benefits by operationally operating the first affinity formula with Sixth Wave in Michigan. In accordance with our signed Memorandum of Understanding, we plan to acquire a minimum of 3 Affinity Units ™ to place elsewhere in the coming months,” he added.
Based on existing homogenization procedures with oconsistent (POE), the formula will be to process approximately 6 kg of high purity final distillate each and every 10 hours of oconsistence with the largest production unit will be the ability to generate finished distillate of approximately 14 kg / 10 hours of constant intake with or more than 30 kg / day, exceeding the company’s target of 20 kg/day. Sixth Wave will start generating profits with the initial formula as soon as the optimization tests are completed. A single production formula will be to generate approximately C$2. 25 million consistent with the year based on a 300-day production schedule while achieving load savings for the authorized producer/higher yield that is expected to nearly double affinity-related license prices ™.
Sixth Wave expects to see continued expansion in the hashish sector such as state-by-state legalization efforts and a prospective federal breakthrough in the United States. Act. Legalization will encourage demand for hashish processing capacity and demand the Affinity system ™.
The Company is in talks with other early adopters who have a significant presence in the industry in Canada and the United States. In addition, SIXW is in joint venture negotiations with a mobile biological expansion company that has decided that SIXW will lead its global progression of hashish products. as well as other high-value plants and roots used in food, nutraceuticals and medicines.
About the Sixth Wave
Sixth Wave is a nanotechnology company with patented technologies that focus on the extraction and detection of target ingredients at the molecular point. Highly specialized molecular fingerprint polymers (PIM). The company is commercially implementing its Affinity cannabinoid purification system ™, as well as IXOS®, a diversity of extractive polymers for the gold mining industry. The Company is also in the progression phase of an immediate virus diagnostic check under the Accelerated MIPs (AMIPS ™) label.
Sixth Wave can design, expand and commercialize MIP responses in a wide variety of industries. The company focuses on highly applicable nanotechnology architectures for the detection and separation of viruses, biogenic amines and other pathogens, for which the company has products in expansion stages.
To learn more about Sixth Wave, visit our online page at: www. sixthwave. com.
ON BEHALF OF THE BOARD OF DIRECTORS
“Jonathan Gluckman” Jonathan Gluckman, Ph. D. , President and Chief Executive Officer
For information, please contact the company: Phone: (801) 582-0559 Email: info@sixthwave. com
Cautionary Notes
This press release includes certain statements that could possibly be considered “forward-looking statements”, adding imaginable statements relating to the intended use of the products and the functionality of the IXOS®, Affinity ™ and AMIPs ™ technologies. All statements in this press release, other than statements of ancient fact, that address occasions or long-term progressions that the Company expects, are forward-looking statements. Although the Company believes that the expectations expressed in those forward-looking statements are based on conservative assumptions, those statements are not promises of long-term functionality, and the actual occasions or progressions may differ materially from those in the forward-looking statements. These forward-looking statements necessarily involve known and unknown threats and insecurities, which could possibly cause the Company’s actual functionality and monetary effects over long-term periods to differ materially from any expressed or implied long-term functionality or effects projections. through those forward-looking statements. In particular, the successful progression and commercialization of IXOS®, Affinity ™ or AMIPs ™ technologies is subject to the threat of unsuccessful success, uncertainty of medical product progression, uncertain timing, or availability of regulatory approvals. required. Fix lack of track record in product progression for secure programs and desire for additional capital to bring out product progression activities. The price of any eventually evolved product can also be adversely affected if patents are not granted. The Company has not yet applied for regulatory approval for the use of this product from a regulatory body.
To view the original edition of this press release, https://www. newsfilecorp. com/release/104142